Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Nikanjam

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Melanoma Research|May 3, 2026
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinomaTali Azenkot, Mina Nikanjam, Soham Mhatre, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experienceMina Nikanjam, Desiré Kabamba, Tim R Cressey, et al.
Cancer Medicine|December 31, 2025
Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory SystemMina Nikanjam, Shumei Kato, Daisuke Nishizaki, et al.
Biochemical Pharmacology|December 9, 2019
Development and preclinical pharmacology of a novel dCK inhibitor, DI-87Soumya Poddar, Edmund V Capparelli, Ethan W Rosser, et al.
European Journal of Clinical Pharmacology|March 23, 2021
S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adultsLana Tran, Mina Nikanjam, Edmund V Capparelli, et al.
Therapeutic Drug Monitoring|January 16, 2023
Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic ApproachJoseph Piscitelli, Mina Nikanjam, Edmund V Capparelli, et al.
Journal of Clinical Pharmacology|September 26, 2018
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through AdulthoodJincheng Yang, Mina Nikanjam, Brookie M Best, et al.
Molecular Cancer Therapeutics|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|May 5, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Oncology|September 4, 2020
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patientsLindsey M Charo, Ramez N Eskander, Ryosuke Okamura, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Melanoma Research|May 3, 2026
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinomaTali Azenkot, Mina Nikanjam, Soham Mhatre, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experienceMina Nikanjam, Desiré Kabamba, Tim R Cressey, et al.
Cancer Medicine|December 31, 2025
Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory SystemMina Nikanjam, Shumei Kato, Daisuke Nishizaki, et al.
Biochemical Pharmacology|December 9, 2019
Development and preclinical pharmacology of a novel dCK inhibitor, DI-87Soumya Poddar, Edmund V Capparelli, Ethan W Rosser, et al.
European Journal of Clinical Pharmacology|March 23, 2021
S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adultsLana Tran, Mina Nikanjam, Edmund V Capparelli, et al.
Therapeutic Drug Monitoring|January 16, 2023
Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic ApproachJoseph Piscitelli, Mina Nikanjam, Edmund V Capparelli, et al.
Journal of Clinical Pharmacology|September 26, 2018
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through AdulthoodJincheng Yang, Mina Nikanjam, Brookie M Best, et al.
Molecular Cancer Therapeutics|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Cancer Therapeutics|May 5, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to ImmunotherapyPeter Moussa, Razelle Kurzrock, Daisuke Nishizaki, et al.
Molecular Oncology|September 4, 2020
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patientsLindsey M Charo, Ramez N Eskander, Ryosuke Okamura, et al.
Pageof 7